Here's good news for women who wish to have babies, as a study has found that a minimal invasive treatment can help restore fertility in women with uterine fibroids - smooth muscle tumors of the uterus.
Uterine fibroids, abnormal masses of fiber and muscle tissue in the wall of the uterus, are considered one of the most common causes of infertility and complications related to pregnancy.
Uterine fibroid embolization (UFE) is a less invasive option that involves injection of an embolic agent, typically made up of very small beads, into the uterine arteries to block the blood supply to the uterus and fibroids. As the fibroids die and begin to shrink, the uterus fully recovers.
The standard treatment option for such women is myomectomy, or surgical removal of the fibroids.
However, myomectomy is not always possible or effective and can result in major complications including hysterectomy, according to study co-author Joao Martins Pisco from Radiological Society of North America.
UFE can be performed in patients with a prior myomectomy or in vitro fertilization (IVF).
Researchers assessed pregnancy rates in 359 women with uterine fibroids, who were unable to conceive and underwent either conventional or partial UFE.
After an average follow-up of almost six years, 149 of the 359 women, or 41.5 percent, had become pregnant one or more times and 131 gave birth to a total of 150 babies.
It was the first pregnancy for more than 85 percent of the women, who gave birth.
The procedures had a clinical success rate of approximately 79 percent for fibroid-related symptoms.
Complication rates were 14.6 percent for partial UFE and 23.1 percent for conventional UFE.
"Our findings show that UFE is a fertility-restoring procedure in women with uterine fibroids, who wish to conceive and pregnancy following UFE appears to be safe with low morbidity," Dr. Pisco said.
"In our study there are now almost 200 newborns following UFE," Dr. Pisco said.
The according to a new study published online in the journal of Radiology.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
